Cetuximab for Lip Squamous Cell Carcinoma Treatment
Author Information
Author(s): Muacevic Alexander, Adler John R, Alchaikh Hassan Ruba, Gafarzadeh Zahra, Salmasi Shiva, Hyams David M, Dasanu Constantin A
Primary Institution: Eisenhower Health, Rancho Mirage, USA
Hypothesis
Can neoadjuvant cetuximab lead to a complete pathologic response in locally advanced lip squamous cell carcinoma?
Conclusion
The patient achieved a complete pathologic response to neoadjuvant cetuximab therapy.
Supporting Evidence
- Cetuximab led to a significant reduction in tumor size.
- The patient had no signs of recurrence at the 24-week follow-up.
- This is the first documented case of cetuximab used as neoadjuvant treatment for lip SCC.
Takeaway
A man with lip cancer got better after taking a medicine called cetuximab before surgery, showing that it can help treat this type of cancer.
Methodology
The patient received neoadjuvant cetuximab therapy followed by radical tumor resection.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
An 81-year-old Caucasian male with a history of multiple comorbidities.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website